October 24th 2025
For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.
October 20th 2025
The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.
Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.
The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.
October 19th 2025
Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.
Tislelizumab Regimen Exhibits Improved Survival in Locally Advanced ESCC
Patients with ESCC treated in 2 tislelizumab-based arms experienced higher composite complete response rates compared to chemoradiotherapy alone.
Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma
Overall survival data in the IMbrave152/SKYSCRAPER-14 study are not anticipated to show statistical significance.
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.
Novel Agent Meets End Points in COMPETE Trial for GEP-NETs
ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.
XTR008 Significantly Extends Progression-Free Survival in SSTR+ GEP-NETs
XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.
Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer
A numerically greater response rate with regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.
Durvalumab Plus FLOT Shows OS Improvement in Resectable Gastric Cancer
A survival analysis stratified by demographic and clinical characteristics revealed an OS benefit was observed with across key subgroups.
Lenvatinib-Based Regimen Does Not Significantly Improve OS in Advanced ESCC
Meta: Safety outcomes, including the treatment-related AEs and AEs leading to treatment discontinuation, were consistent with or without lenvatinib in ESCC.
Neoadjuvant FOLFIRINOX Shows Comparable Survival vs Chemoradiation in PDAC
Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.
FDA Grants Fast Track Designation to NG-350A for pMMR Rectal Cancer
Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.
Taking Stock of Immune Effector Cell Therapy Developments in GI Cancers
Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
Survival results were similar among all patients and PD-L1 subgroups with the domvanalimab regimen in gastroesophageal junction adenocarcinoma.
212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs
A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.
Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC
Atebimetinib with gemcitabine and nab-paclitaxel achieved 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.
Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC
Mitazalimab/Chemo Yields Promising Survival/Responses in Untreated PDAC
At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.
3 Things You Should Know About Data Presented at ESMO GI
New therapies for hepatobiliary cancers show promise, expanding treatment options for patients with advanced disease and challenging conditions.
TP53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies
Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type genes or GOF mutations.
ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors
An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.
Idylla CDx MSI Test Earns FDA Approval in MSI-H Colorectal Cancer
The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.
New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening
The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.
Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer
In patients with rectal cancer, the median OS was 12 years in the chemotherapy and radiation therapy group vs 24 years in the chemotherapy alone group.
Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC
Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.
Chemoradiation Shows Long-Term Clinical Benefit in High-Risk Gastric Cancer
The incidence of grade 3 to 4 acute toxicities was similar in patients with high-risk gastric cancer treated with chemoradiation or chemotherapy.
Dendritic Cell Vaccine Shows Preliminary Activity in Advanced HCC
The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.
Pembrolizumab Combo Improves pCR Rate in Advanced Gastric/GEJ Cancer
Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.
Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC
Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.
Addition of Radiotherapy to Systemic Chemotherapy Improves Survival in ESCC
Although radiotherapy was safe and well tolerated in patients with esophageal squamous cell carcinoma, more research is needed to confirm these results.
pCR Does Not Correlate With Survival in Rectal Cancer
A meta-analysis did not find any correlation between pathologic complete response and overall survival or disease-free survival in patients with rectal cancer.
mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.